Report of the Japan diabetes society/Japanese cancer association joint committee on diabetes and cancer

Cancer Science

Volumn 104, Issue 7, 2013, Pages 965-976

  Kasuga, Masato ^a   Ueki, Kohjiro ^b   Tajima, Naoko ^c   Noda, Mitsuhiko ^a   Ohashi, Ken ^d   Noto, Hiroshi ^a   Goto, Atsushi ^a   Ogawa, Wataru ^e   Sakai, Ryuichi ^f   Tsugane, Shoichiro ^f   Hamajima, Nobuyuki ^g   Nakagama, Hitoshi ^a   Tajima, Kazuo ^h   Miyazono, Kohei ^b   Imai, Kohzoh ⁱ  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^g NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; HISTONE H3; INSULIN; INSULIN GLARGINE; INSULIN RECEPTOR; METFORMIN; SOMATOMEDIN C;

ADIPOCYTE; AGING; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; COLORECTAL CANCER; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRINKING BEHAVIOR; ENDOMETRIUM CANCER; FOOD INTAKE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMOBILIZATION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; JAPAN; KIDNEY CANCER; LIVER CANCER; MEDICAL SOCIETY; META ANALYSIS (TOPIC); NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY CANCER; PANCREAS CANCER; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; JAPAN; MALE; META-ANALYSIS AS TOPIC; NEOPLASMS; RISK FACTORS;

EID: 84880728145     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12203     Document Type: Article

References (132)

1. Masato K, Kohjiro U, Naoko T et al. Report of the Japan Diabetes Society/Japanese Cancer Association Joint Committee on Diabetes and Cancer. J Japan Diab Soc 2013; 56: 374-90. (in Japanese).
2. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009; 16: 1103-23.
3. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2056-62.
4. Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer 2007; 96: 507-9.
5. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004; 47: 1071-8.
6. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995; 273: 1605-9.
7. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007; 50: 1365-74.
8. Huxley R, Ansary-Moghaddam A, de Gonzalez AB, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-83.
9. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 1679-87.
10. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49: 2819-23.
11. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121: 856-62.
12. Mitri J, Castillo J, Pittas AG. Diabetes and risk of non-Hodgkin's lymphoma. Diabetes Care 2008; 31: 2391-7.
13. Noto H, Osame K, Sasazuki T, Noda M. Substantially increased risk of cancer in patients with diabetes mellitus A systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 2010; 24: 345-53.
14. Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr Pract 2011; 17: 616-28.
15. Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010; 60: 207-21.
16. Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-85.
17. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006; 166: 1871-7.
18. Inoue M, Noda M, Kurahashi N et al. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 2009; 18: 240-7.
19. Inoue M, Kurahashi N, Iwasaki M et al. Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control 2009; 20: 741-50.
20. Noto H, Tsujimoto T, Noda M. Significantly increased risk of cancer in diabetes mellitus patients: a meta-analysis of epidemiological evidence in Asians and non-Asians. J Diabetes Invest 2012; 3: 24-33.
21. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-80.
22. Barone BB, Yeh HC, Snyder CF et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008; 300: 2754-64.
23. Barone BB, Yeh HC, Snyder CF et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 2010; 33: 931-9.
24. Yoon JM, Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes mellitus increases the risk of gastric cancer: a meta-analysis. World J Gastroenterol 2013; 19: 936-45.
25. Center for Cancer Control and Information Services, National Cancer Center, Japan. Cumulative Cancer Incidence/Mortality Risk. [Cited 31 May 2013.] Available from URL: http://ganjoho.jp/data/professional/statistics/backnumber/2012/fig10.pdf
26. Center for Cancer Control and Information Services, National Cancer Center, Japan. Monitoring of Cancer Incidence in Japan (MCIJ2007) (in Japanese). [Cited 31 May 2013.] Available from URL: http://ganjoho.jp/data/professional/statistics/odjrh3000000hwsa-att/mcij2007_report.pdf
27. Ogawa W, Kasuga M. Mechanism of insulin action and diabetes mellitus. Seikagaku 2003; 75: 1332-44 (in Japanese).
28. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
29. Novosyadlyy R, Lann DE, Vijayakumar A et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 2010; 70: 741-51.
30. Gogg S, Smith U, Jansson PA. Increased MAPK activation and impaired insulin signaling in subcutaneous microvascular endothelial cells in type 2 diabetes: the role of endothelin-1. Diabetes 2009; 58: 2238-45.
31. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006; 17: 328-36.
32. Nakae J, Kido Y, Accili D. Distinct and overlapping functions of insulin and IGF-1 receptors. Endocr Rev 2001; 22: 818-35.
33. Sung MK, Yeon JY, Park SY, Park JH, Choi MS. Obesity-induced metabolic stresses in breast and colon cancer. Ann N Y Acad Sci 2011; 1229: 61-8.
34. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270-82.
35. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-91.
36. Dandona P, Dhindsa S. Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab 2011; 96: 2643-51.
37. Bruning JC, Gautam D, Burks DJ et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122-5.
38. Chang YC, Chuang LM. The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication. Am J Transl Res 2010; 2: 316-31.
39. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107: 1058-70.
40. Akatsuka S, Toyokuni S. Genome-wide assessment of oxidatively generated DNA damage. Free Radic Res 2012; 46: 523-30.
41. Ohsawa S, Sato Y, Enomoto M, Nakamura M, Betsumiya A, Igaki T. Mitochondrial defect drives non-autonomous tumour progression through Hippo signalling in Drosophila. Nature 2012; 490: 547-51.
42. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
43. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol 2010; 299: F14-25.
44. Pirola L, Balcerczyk A, Okabe J, El-Osta A. Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 2010; 6: 665-75.
45. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150: 12-27.
46. Meng D, Mei A, Liu J et al. NADPH oxidase 4 mediates insulin-stimulated HIF-1alpha and VEGF expression, and angiogenesis in vitro. PLoS One 2012; 7: e48393.
47. de Heredia FP, Gomez-Martinez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc 2012; 71: 332-8.
48. Bondia-Pons I, Ryan L, Martinez JA. Oxidative stress and inflammation interactions in human obesity. J Physiol Biochem 2012; 68: 701-11.
49. Back SH, Kaufman RJ. Endoplasmic reticulum stress and type 2 diabetes. Annu Rev Biochem 2012; 81: 767-93.
50. Flamment M, Hajduch E, Ferre P, Foufelle F. New insights into ER stress-induced insulin resistance. Trends Endocrinol Metab 2012; 23: 381-90.
51. Garg AD, Kaczmarek A, Krysko O, Vandenabeele P, Krysko DV, Agostinis P. ER stress-induced inflammation: does it aid or impede disease progression? Trends Mol Med 2012; 18: 589-98.
52. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
53. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002; 23: 599-622.
54. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011; 12: 715-23.
55. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab 2013; 17: 185-96.
56. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev 2012; 33: 547-94.
57. Villarreal-Molina MT, Antuna-Puente B. Adiponectin: anti-inflammatory and cardioprotective effects. Biochimie 2012; 94: 2143-9.
58. Park J, Scherer PE. Leptin and cancer: from cancer stem cells to metastasis. Endocr Relat Cancer 2011; 18: C25-9.
59. Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA. Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control 2012; 23: 991-1008.
60. Ministry of Health, Labour and Welfare, Japan (in Japanese). [Cited 31 May 2013.] Available from URL: http://www.mhlw.go.jp/stf/houdou/2r98520000020qbb-att/2r98520000021c0o.pdf
61. Center for Cancer Control and Information Services, National Cancer Center, Japan (in Japanese). [Cited 31 May 2013.] Available from URL: http://ganjoho.jp/public/statistics/pub/statistics02.html
62. van Dam RM, Hu FB. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA 2005; 294: 97-104.
63. Yu X, Bao Z, Zou J, Dong J. Coffee consumption and risk of cancers: a meta-analysis of cohort studies. BMC Cancer 2011; 11: 96.
64. Japan Diabetes Society. Evidence-based Practice Guideline for the Treatment of Diabetes in Japan 2010. Tokyo: Nankodo, 2010 (in Japanese).
65. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012; 35(Suppl 1): S11-63.
66. Vainio H, Bianchini F. Weight Control and Physical Activity. Lyon: IARC Press, 2002.
67. Tsugane S. The Development and Evaluation of Cancer Prevention Strategies in Japan. 2011 research report. The third-term comprehensive control research for cancer, Ministry of Health, Labour and Welfare. (in Japanese).
68. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-38.
69. Adams TD, Gress RE, Smith SC et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357: 753-61.
70. Inoue M, Sobue T, Tsugane S. Impact of body mass index on the risk of total cancer incidence and mortality among middle-aged Japanese: data from a large-scale population-based cohort study-the JPHC study. Cancer Causes Control 2004; 15: 671-80.
71. Barclay AW, Petocz P, McMillan-Price J et al. Glycemic index, glycemic load, and chronic disease risk-a meta-analysis of observational studies. Am J Clin Nutr 2008; 87: 627-37.
72. Kushi LH, Byers T, Doyle C et al., American Cancer Society N, Physical Activity Guidelines Advisory C. American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2006; 56: 254-81.
73. Kastorini CM, Panagiotakos DB. Dietary patterns and prevention of type 2 diabetes: from research to clinical practice; a systematic review. Curr Diabetes Rev 2009; 5: 221-7.
74. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 2002; 11(Suppl): 3456S-64S.
75. Lee IM. Physical activity and cancer prevention-data from epidemiologic studies. Med Sci Sports Exerc 2003; 35: 1823-7.
76. Inoue M, Yamamoto S, Kurahashi N, Iwasaki M, Sasazuki S, Tsugane S. Daily total physical activity level and total cancer risk in men and women: results from a large-scale population-based cohort study in Japan. Am J Epidemiol 2008; 168: 391-403.
77. Jeon CY, Lokken RP, Hu FB, van Dam RM. Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review. Diabetes Care 2007; 30: 744-52.
78. Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-44.
79. World Health Organization International Agency for Research on Cancer. Tobacco Smoke and Involuntary Smoking. Lyon: IARC Press, 2004.
80. World Health Organization International Agency for Research on Cancer. Smokeless Tobacco and Some Tobacco-Specific N-Nitrosamines. Lyon: IARC Press, 2007.
81. Foy CG, Bell RA, Farmer DF, Goff DC Jr, Wagenknecht LE. Smoking and incidence of diabetes among U.S. adults: findings from the Insulin Resistance Atherosclerosis Study. Diabetes Care 2005; 28: 2501-7.
82. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007; 298: 2654-64.
83. Oba S, Noda M, Waki K et al. Smoking cessation increases short-term risk of type 2 diabetes irrespective of weight gain: the Japan Public Health Center-Based Prospective Study. PLoS One 2012; 7: e17061.
84. Secretan B, Straif K, Baan R et al., Group WHOIAfRoCMW. A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009; 10: 1033-4.
85. Inoue M, Wakai K, Nagata C et al. Alcohol drinking and total cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 2007; 37: 692-700.
86. World Health Organization International Agency for Research on Cancer. Alcohol Consumption and Ethyl Carbamate. Lyon: IARC Press, 2010.
87. Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Inter Med 2004; 140: 211-9.
88. Baliunas DO, Taylor BJ, Irving H et al. Alcohol as a risk factor for type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 2009; 32: 2123-32.
89. Seike N, Noda M, Kadowaki T. Alcohol consumption and risk of type 2 diabetes mellitus in Japanese: a systematic review. Asia Pac J Clin Nutr 2008; 17: 545-51.
90. Park EJ, Lee JH, Yu GY et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208.
91. Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci 2011; 7: 1003-15.
92. Itoh M, Suganami T, Nakagawa N et al. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am J Pathol 2011; 179: 2454-63.
93. Minamino T, Orimo M, Shimizu I et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med 2009; 15: 1082-7.
94. Gonzalez-Rodriguez A, Mas-Gutierrez JA, Mirasierra M et al. Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging. Aging Cell 2012; 11: 284-96.
95. Hemkens LG, Grouven U, Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-44.
96. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745-54.
97. Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52: 1755-65.
98. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-77.
99. Ruiter R, Visser LE, van Herk-Sukel MP et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012; 55: 51-62.
100. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-28.
101. Blin P, Lassalle R, Dureau-Pournin C et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 2012; 55: 644-53.
102. Fagot JP, Blotiere PO, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of cancer compared with other basal insulins?: a French nationwide cohort study based on national administrative databases. Diabetes Care 2013; 36: 294-301.
103. Yang X, Ko GT, So WY et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 2010; 59: 1254-60.
104. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011; 54: 2009-15.
105. Yang X, So WY, Ma RC et al. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 2010; 90: 343-51.
106. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the taiwanese. Exp Diabetes Res 2012; 2012: 413782.
107. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009; 46: 279-84.
108. United States Food and Drug Administration. BYETTA (exenatide) injection [Amylin Pharmaceuticals, Inc.]. [Cited 31 May 2013.] Available from URL: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=751747da-7c1f-41ad-b1a6-a6d920f70599
109. United States Food and Drug Administration. VICTOZA (liraglutide (rdna origin) injection) injection, solution [Novo Nordisk]. [Cited 31 May 2013.] Available from URL: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
110. Pharmaceuticals and Medical Devices Agency, Japan (in Japanese). [Cited 31 May 2013.] Available from URL: http://www.info.pmda.go.jp/go/pack/2499411G1026_2_01/
111. Pharmaceuticals and Medical Devices Agency, Japan (in Japanese). [Cited 31 May 2013.] Available from URL: http://www.info.pmda.go.jp/go/pack/2499410G1021_1_05/
112. Pharmaceuticals and Medical Devices Agency, Japan (in Japanese). [Cited 31 May 2013.] Available from URL: http://www.info.pmda.go.jp/go/pack/3969010F1034_2_12/
113. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-6.
114. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011; 27(Suppl 3): 57-64.
115. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
116. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011; 34: 1369-71.
117. Lewis JD, Ferrara A, Peng T et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-22.
118. Azoulay L, Yin H, Filion KB et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012; 344: e3645.
119. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012; 55: 1953-62.
120. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012; 35: 278-80.
121. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012; 184: E675-83.
122. Pharmaceuticals and Medical Devices Agency, Japan (in Japanese). [Cited 31 May 2013.] Available from URL: http://www.info.pmda.go.jp/go/pack/3969007F1024_1_29/
123. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012; 7: e33411.
124. Stevens RJ, Ali R, Bankhead CR et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012; 55: 2593-603.
125. Suissa S, Azoulay L. Metformin and the Risk of Cancer: time-related biases in observational studies. Diabetes Care 2012; 35: 2665-73.
126. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci 2012; 122: 253-70.
127. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804-12.
128. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol 2012; 29: 1314-27.
129. Bangalore S, Kumar S, Kjeldsen SE et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324, 168 participants from randomised trials. Lancet Oncol 2011; 12: 65-82.
130. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
131. Rothwell PM, Price JF, Fowkes FG et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-12.
132. Ministry of Health, Labour and Welfare, Japan (in Japanese). [Cited 31 May 2013.] Available from URL: http://www.mhlw.go.jp/bunya/kenkou/dl/gan_kenshin01.pdf